A Phase 3 interventional study of Quizartinib and Midostaurin in Acute Myeloid Leukemia, sponsored by University Hospital, Toulouse. Not yet recruiting at 55 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Leukemia, Myeloid, Acute with a site in France — 64 open to participants now, 96 under way, 21 of them phase 3. Leukemia, Myeloid, Acute · France.
Among the 342 studies in Leukemia, Myeloid, Acute with a site in France, this one is the 4th largest by planned enrollment of the 289 interventional ones that give a count, is the only one that started in 2027, is one of 77 in phase 3, reaches primary completion later than 94 of the 95 other live ones, and was the 342nd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →64 of the 342 studies in Leukemia, Myeloid, Acute with a site in France are open now. Recruiting first, the newest first:
AbbVie · Sites in France, United States, Austria and 4 more countries
Ages 18+
AbbVie · Sites in France, United States, Australia and 4 more countries
Ages 6 mo–17 yrs
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 106 · Phase 2 123 · Phase 3 84 · Phase 4 3
First in 1993; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,290 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 100 across the 289 interventional studies, 180 across the 52 observational. Of the 209 that completed or were terminated, 80 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 342 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 6 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
27 of the studies in Leukemia, Myeloid, Acute with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
Add all 27 to your calendar (.ics) → With an account.
Among the 342 studies in Leukemia, Myeloid, Acute with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The treatment of younger AML patients fit for intensive chemotherapy (IC) has long been based on a combination of an anthracycline and cytarabine as induction, followed by high-dose cytarabine (HDAC) consolidation, and possibly allogeneic stem-cell transplantation at least in non-favorable risk AML patients. Even if new agents like gemtuzumab ozogamicin (GO), FLT3 inhibitors, or CPX-351 have been approved to treat some patient subsets, there has been no major therapeutic advances to date in this field.
The first multicenter trial from the ALFA-FILO intergroup (Backbone InterGroup trial-1, BIG-1; NCT02416388; PHRC2010-03) randomly explored various standard intensive chemotherapy strategies, including higher-dose idarubicin vs. high-dose daunorubicin (DNR) and intermediate-dose cytarabine (IDAC) vs. HDAC in patients (18-60 years) with newly-diagnosed AML. This first part of the study, which enrolled 1405 participants between 01/2015 and 05/2019, showed that the benefit/risk ratio favored high-dose DNR for remission induction and IDAC consolidation, establishing the national standard treatment for younger AML patients. Six-year OS was 53.4% showing that there is still considerable room for improvement in this younger patient population.
High-throughput sequencing and multiparametric flow cytometry have significantly improved prognostic classifications and the evaluation of response to therapy through the quantification of measurable residual disease (MRD). Many studies have shown that the higher the MRD, the higher the risk of relapse and death; and recent guidelines have included MRD in the response criteria. Achieving complete remission without MRD is a major goal after first-line treatment to guide subsequent treatments, including transplantation. Furthermore, MRD follow-up in patients who achieved complete remission is becoming a major issue, as patients treated for molecular relapse appear to have a better prognosis than patients treated for morphological relapse. Preliminary data also showed encouraging results from salvage treatment at the time of MRD relapse.
Quizartinib (a second-generation FLT3-ITD inhibitor) and venetoclax (the first-in-class BCL-2 inhibitor) have been recently approved for the treatment of AML. Quizartinib was approved on the basis of a placebo-controlled trial but its added value compared to midostaurin (first FLT3 inhibitor available in this indication since 2018) has never been prospectively explored. Although venetoclax was approved for first line therapy of patients who are unfit for intensive chemotherapy, it is widely used in relapsed or refractory younger patients. Venetoclax combined with intensive salvage chemotherapy is feasible and induce a high rate of CR. However, no prospective, randomized trial demonstrated venetoclax efficacy in this setting.
Multicenter umbrella trial integrating 3 sub-studies with eligibility criteria based on molecular diagnosis and an MRD-guided treatment program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for sub-study 1 11 1. Presence of FLT3 internal tandem duplication activating mutation in bone marrow (allelic ratio ≥ 0.03) 12-1. Receiving standard 7+3 induction chemotherapy regimen as specified in the protocol 13 1. Serum electrolytes within the institution's normal limits: potassium, calcium (total calcium, calcium corrected for serum albumin in case of hypoalbuminemia, or ionized calcium), and magnesium.
Additional inclusion criteria for sub-study 2 11-2. (no response) or CR/CRh/CRi with positive Measurable Residual Disease by Multiparameter Flow Cytometry in bone marrow (≥ 0.1%) after one cycle of 7+3 induction 12 2. Eligible for a second cycle of intensive chemotherapy
Additional inclusion criteria for sub-study 3 11 3. CR/CRh/CRi without Measurable Residual Disease by Multiparameter Flow Cytometry in bone marrow (\< 0.1% OR \< Limit of Detection) after one cycle of 7+3 induction.
Exclusion Criteria:
Additional exclusion criteria for sub-study 1 11 1. Patients with Core-Binding Factor Acute myeloid leukemia 12 1. Prior treatment with quizartinib or other FLT3 inhibitors 13 1. Uncontrolled or significant cardiovascular disease, including any of the following:
15-1. Treatment with any strong or moderate inducers within 2 weeks or 5 half-lives of randomization whichever is longer
Additional exclusion criteria for sub-study 2 11 2. Patients with acute myeloid leukemia with FLT3 internal tandem duplication mutation without Core-Binding Factor 12 2. Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 13 2. Documented uncontrolled fungal infection (positive blood test and cultures) 14 2. Prior venetoclax exposure
Additional exclusion criteria for sub-study 3 11 3. Patients with acute myeloid leukemia with FLT3 internal tandem duplication mutation without Core-Binding Factor
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Addition of quizartinib to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
Drug: Quizartinib
Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
Drug: Midostaurin
Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
Drug: Venetoclax
High-dose cytarabine only after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
Drug: High-dose cytarabine
MRD-guided program in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients with FLT3 internal tandem duplication) and who achieved Complete Remission/Complete Remission with partial hematologic recovery/Complete Remission with incomplete hematologic recovery without Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction.
Sub-study 1 : addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
Sub-Study 1: Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
Sub-Study 2 : Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
High-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
Sub-Study 1 : MRD response
Determine whether the addition of quizartinib to induction chemotherapy (7+3) results in a significant improvement in Measurable Residual Disease response after one cycle, as assessed by Polymerase Chain Reaction-Next-Generation Sequencing, compared to midostaurin added to 7+3 in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication acute myeloid leukemia without Core-Binding Factor acute myeloid leukemia.
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Sub-Study 2 : MRD response venetoclax
Determine whether the addition of venetoclax to high-dose cytarabine results in a significant improvement in MRD response after one cycle, as assessed by MFC, compared to high-dose cytarabine alone in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative acute myeloid leukemia (including Core-Binding Factor acute myeloid leukemia patients with FLT3 internal tandem duplication) and with a suboptimal response to 7+3 induction (i.e., no response or CR/CRh/CRi with positive Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction).
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Sub-Study 3 : Overall survival
Describe the effect of an Measurable Residual Disease-guided program on overall survival in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative acute myeloid leukemia (including Core-Binding Factor acute myeloid leukemia patients with FLT3 internal tandem duplication) who achieved CR/CRh/CRi without Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 53 months
Sub-Study 1 : MRD response after 2 cycles
Determine whether the addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy results in a significant improvement in Measurable Residual Disease response after 2 cycles (combined induction and first consolidation, as assessed by Polymerase Chain Reaction-Next-Generation Sequencing, compared to the addition of Midostaurin in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication acute myeloid leukemia without Core-Binding Factor acute myeloid leukemia.
Time frame: At the end of Cycle 2 (each cycle is 28 days)
Start is estimated for Jan 2027; primary completion for Dec 2035, 107 months later.
Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 107 months is above that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →